Sepideh Darbandi, DO
Cardiovascular Disease · Mason City, IANPI 1790217677
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,313 of the $8,647 with a category attached, or 61.4%. Abbott accounts for 64.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $4,851 and has fallen 89.2% since, to $525 in 2025. Among cardiovascular disease clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $48.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$645
- AstraZeneca$595
- Boston Scientific$490
- Actelion Pharmaceuticals US, Inc.$279
- Boehringer Ingelheim$174
- plus $901 from 15 others
What the payments were for
- Grants$3494%
- Travel & lodging$2,26726%
- Food & beverage$5,31361%
- Education$7188%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 91 | $5,563 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 40 | $645 |
| AstraZeneca | 11 | $595 |
| Boston Scientific | 2 | $490 |
| Actelion Pharmaceuticals US, Inc. | 4 | $279 |
| Boehringer Ingelheim | 6 | $174 |
| Johnson & Johnson | 4 | $160 |
| Abiomed | 3 | $140 |
| Novartis | 6 | $139 |
| Esperion Therapeutics, Inc. | 1 | $113 |
| Medtronic | 1 | $100 |
| Novo Nordisk | 2 | $69 |
| Atricure, Inc. | 1 | $39 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Biotronik Inc. | 1 | $18 |
| Getinge USA Sales, LLC | 1 | $17 |
| Pfizer | 1 | $15 |
| Teleflex LLC | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Terumo Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,647 in reported general payments places this provider in the 90th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $159,445 |
| JardianceEmpagliflozin | 81 | $72,090 |
| XareltoRivaroxaban | 26 | $30,335 |
| Repatha SureclickEvolocumab | 36 | $21,168 |
| EntrestoSacubitril/Valsartan | 18 | $15,847 |
| BrilintaTicagrelor | 18 | $15,261 |
| Praluent PenAlirocumab | 12 | $6,679 |
| Metoprolol Succinate | 462 | $6,478 |
| Dofetilide | 14 | $6,275 |
| Torsemide | 180 | $2,834 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 183 | $2,626 |
| Ranolazine ErRanolazine | 36 | $2,187 |
| Atorvastatin Calcium | 240 | $1,993 |
| Losartan Potassium | 196 | $1,546 |
| Rosuvastatin Calcium | 109 | $1,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $159,445149 claims |
| Boehringer IngelheimJardiance | $174 | $72,09081 claims |
| Johnson & JohnsonXarelto | $160 | $30,33526 claims |
| NovartisEntresto | $139 | $15,84718 claims |
| AstraZenecaBrilinta | $595 | $15,26118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Mason City
- Noor SubahMason City$8K
- Tauseef AkhtarMason City$8K
- Michael SpoonerMason City$7K
- Radu HagauMason City$3K
- Brett CarlsonMason City$2K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.